Search Technologies

The National Cancer Institute (NCI) seeks licensing of Bac-2-the-Future, an improved system for the production of recombinant baculovirus.

The National Institutes of Health - Clinical Center (NIH-CC) seeks to license and/or co-develop methods of reading chest x-rays using a deep learning models to detect a disease and describe its contents.

The National Institutes of Health (NIH) Clinical Center (CC) seeks Cooperative Research and Development and/or license agreements for Transperineal Ultrasound-Guided Prostate Biopsy

Pre-clinical radiotracer biomedical research involves the use of compounds labeled with radioisotopes, including radio-ligand bio-distribution studies, cell binding studies, immune cell labeling techniques, and α-based therapies. Before this Micro-Dose Calibrator, measurement of pre-clinical level dosage for small animal studies was inaccurate and unreliable. This dose calibrator is a prototype ready for customer testing and scale-up. It is designed to accurately measure radioactive doses in the range of 50 nCi (1.8 kBq) to 100 µCi (3.7 MBq) with 99% precision. The NCI seeks co-development or licensing to commercialize it. Alternative uses will be considered.

Photolithographic methods are used to construct mimetic silicone hydrogel pillars that have, for example, a 20:1 height to diameter ratio.

Device is used to guide a stream of oxygen or carbon dioxide over a dish of cells during fluorescence microscopy. Invention includes the 3D printing software to create the device. The device makes it possible to easily provide a steady source of oxygen or carbon dioxide to cells while operating a fluorescent microscope to oxidize fluorophores for later visualization in electron microscopy. NCI seeks commercial partners to license this technology.

The NCI seeks licensees or co-development partners for this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.

The National Cancer Institute seeks parties interested in collaborative research to evaluate or commercialize a diagnostic tool that can identify new drugs that increase chromosome instability.

This technology is a new generation of rationally designed chelating agents that improve the complexation of Zirconium-89 for PET imaging of cancers.